Argenx Sets May 7 for Q1 Earnings as Analysts Eye $11 Billion Revenue Goal
Amsterdam, Thursday, 30 April 2026.
Argenx will report its Q1 2026 earnings on May 7. Investors are eagerly watching the biotechnology leader, with analysts projecting a massive $11 billion in revenue by 2030.
Regulatory Milestones and the VYVGART Engine
The cornerstone of Argenx’s commercial success remains efgartigimod, marketed as VYVGART [2]. As the first approved neonatal Fc receptor (FcRn) blocker [1][3], the therapy has established a strong foothold in treating IgG-mediated disorders, primarily generalized myasthenia gravis (gMG) [2][3]. Investors tuning into the May 7 update will be highly focused on the imminent May 10, 2026, Prescription Drug User Fee Act (PDUFA) target action date [alert! The source notes this is the target date, but actual FDA action could occur slightly before or on this date] [3]. The U.S. Food and Drug Administration (FDA) is currently reviewing the company’s supplemental Biologics License Application (sBLA) for VYVGART in AChR-Ab seronegative gMG under Priority Review [3].
Long-Term Projections and Institutional Sentiment
Wall Street’s long-term outlook for Argenx reflects significant growth expectations. Analysts project that the firm’s revenue will scale to $9.8 billion by fiscal year 2029, before hitting the $11.0 billion mark in fiscal year 2030 [3]. Earnings per share are expected to follow a similar aggressive upward trajectory, with forecasts predicting an EPS of $53.36 in 2029 and $59.24 in 2030 [3]. Currently, out of the analysts covering the stock, 36 maintain a “Buy” consensus, establishing a median price target of $1,006.00 [3]. A separate breakdown highlights that two equities research analysts have assigned a Strong Buy rating, eighteen suggest a Buy, and four recommend a Hold [4].